Pharma & Biotech
Bayer’s Ruveon Overhaul and Analyst Divergence Signal a Pivotal Moment After a 40% Rally
Bayer has moved decisively to reshape its US glyphosate operations, folding the business into a newly created entity called Ruveon...
BioNTech’s Oncology Ambition Faces a Trio of Tests: Clinical Data, Founder Departure, and Deep Cost-Cutting
BioNTech is entering a period where scientific validation, financial discipline, and leadership transition all converge. The stock closed Tuesday at...
Novo Nordisk Expands Oral Wegovy to UK and New Liver Indication, Implant Study on Horizon
Novo Nordisk is extending its oral Wegovy franchise across multiple fronts simultaneously, with a UK launch, a fresh liver fibrosis...
Two Final Events Hold the Key for Sellas Life Sciences as the Stock Races Ahead of Its Fundamentals
Sellas Life Sciences has turned into a live referendum on a single clinical dataset, with the stock’s eye-popping 594% annual...
Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing
Ocugen has quietly reshaped its financial outlook. In May, the company placed $130 million in convertible notes, carrying a 6.75%...
Bayer’s Rally Faces a New Test: Antidumping Bid vs. Overbought Charts After Court Win
Just five days after a landmark Supreme Court victory, Bayer has opened a second front in its glyphosate saga —...
Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010
July is shaping up as a binary-riddled month for the small-cap biopharma. Two weeks after shareholders cast decisive ballots on...
ImmunityBio’s 369% Surge Meets 13% Short Interest — A Collision Course in Biotech
ImmunityBio has become a battleground stock where two opposing forces are digging in. Retail traders have piled into the biotech...
Onco-Innovations’ Share-Linked Payment Plan Threatens Dilution Even as Nanosoft Boosts ONC010 Manufacturing
The gulf between operational progress and market perception is rarely wider than at Onco-Innovations these days. The oncology biotech has...
Novo Nordisk Faces a Technical Squeeze as Medicare GLP-1 Plan and Analyst Caucus Diverge
The stock has surged more than 16% over the past month, yet the enthusiasm on Wall Street remains conspicuously muted....
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
